Regeneron Reports Results of REGEN-COV Antibody Cocktail in P-III Trial to Prevent COVID-19

March 23, 2021 Auto Bot Clinical Trials, P-III Trial, Prevent, Regeneron, reports, results 0

Shots:

  • The P-III trial involves assessing REGEN-COV (casirivimab & imdevimab, 1200/2400mg, IV) vs PBO in non-hospitalized patients with COVID-19
  • The trial met its 1EPs i.e. showed a reduction in the risk of hospitalization and death with both doses by 70% /71% respectively and met its 2EPs including the ability to reduce symptom duration. The P-II trial showed viral reductions for all REGEN-COV doses tested, including as low as 300 mg
  • Additionally, Regeneron will share new data with regulatory authorities immediately and request that a lower 1,200 mg dose be added to EUA

Click here ­to­ read full press release/ article | Ref: Regeneron | Image: WRGB

The post Regeneron Reports Results of REGEN-COV Antibody Cocktail in P-III Trial to Prevent COVID-19 first appeared on PharmaShots.